Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTristel Regulatory News (TSTL)

Share Price Information for Tristel (TSTL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 450.00
Bid: 440.00
Ask: 460.00
Change: 0.00 (0.00%)
Spread: 20.00 (4.545%)
Open: 450.00
High: 450.00
Low: 450.00
Prev. Close: 450.00
TSTL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK and EU regulatory approval update

26 Feb 2024 07:00

RNS Number : 3374E
Tristel PLC
26 February 2024
 

TRISTEL plc

("Tristel", the "Company", or the "Group")

 

UK and EU regulatory approval update for surface disinfection system

 

Sustainable alternative to commonly used pre-wetted plastic wipes to become available in Europe

 

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products utilising proprietary chlorine dioxide technology, announces that all reviews under the Medical Devices Regulation 2002 ("UK MDR") and the European Union Medical Device Regulation 2017/745 ("EU MDR") for approval of the Company's TANK ClO? Sporicidal Disinfectant system have been successfully concluded and a positive recommendation for UKCA and MDR certification has been made.

 

The TANK system and accompanying capsules are the newest additions to the Cache range, which provides sporicidal surface disinfection in a format which is a sustainable alternative to commonly used pre-wetted plastic wipes.

 

Following MDR approvals Tristel will be able to accelerate sales activity for this product throughout Europe and across geographies that recognise the high standard of safety and quality demonstrated by products conforming to the new EU MDR. The Directors believe that approval, will give Tristel the opportunity to deliver significant growth in sales of the Cache product range going forward, targeting a largely untapped sporicidal surface disinfection market. The Company expects to officially launch these latest products in Europe before the current financial year end on 30 June 2024.

 

For the year ended 30 June 2023 revenues from the Cache range totalled £3.3m, representing 9.2% of total annual turnover.

 

About TANK ClO? Sporicidal Disinfectant and the Cache range (https://thecachecollection.com)

TANK ClO? Sporicidal Disinfectant is a storage and distribution system powered by ClO? sporicidal disinfectant capsules. One TANK ClO? Sporicidal Disinfectant capsule makes 10 litres of sporicidal solution, which is the same as 2,000 sporicidal wipes wetted with 5ml of liquid. Rather than relying on convenience products that do harm once they are disposed of, TANK uses plastic thoughtfully. The core components are reusable, and all the plastic items within the system are recyclable. Users can apply TANK ClO? Sporicidal Disinfectant working solution with a Doser, Foamer or Sprayer, and reduce plastic waste by pairing TANK working solution with any dry wipe.

 

 

The TANK ClO? Sporicidal Disinfectant system

 

 

The broader Cache product range for sporicidal surface disinfection

 

For further information on the TANK ClO? Sporicidal Disinfectant system please view the product brochure here:

https://thecachecollection.com/wp-content/uploads/2021/09/Mkt-Bro-1508-6-TANK-ClO2-Sporicidal-Brochure-EN.pdf

 

Paul Swinney, CEO of Tristel, commented: "Whilst our Cache product range is intended for environmental surfaces, many of the surfaces in a hospital setting are considered medical devices and so it is key for any disinfection products to comply with the new EU Medical Device Regulation. It is a very significant achievement to have concluded all reviews successfully and we expect to receive our recommendation for certification from our Notified Body very shortly. Conformity with MDR will allow us to apply CE marking to these new products and gives us the opportunity to deliver significant growth in sales of the Cache product range going forward."

 

For further information please contact:

 

Tristel plc

Tel: 01638 721 500

Paul Swinney, Chief Executive Officer

www.investors.tristel.com

Liz Dixon, Chief Financial Officer

Walbrook PR Ltd

Tel: 020 7933 8780 or tristel@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Charlotte Edgar

Mob: 07884 664 686

Cavendish Capital Markets Ltd

Tel: 020 7220 0500

Geoff Nash / Charlie Beeson (Corporate Finance)

Sunila de Silva (ECM)

 

About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO2) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the Tristel brand, and under the Cache brand provides products for sporicidal surface disinfection, in a format which is a sustainable alternative to commonly used pre-wetted plastic wipes.

 

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 250 people across 14 subsidiaries selling into 40 countries.

 

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

 

For more information about Tristel's product range please visit: https://tristel.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
REAGZGZZNFRGDZM
Date   Source Headline
19th Nov 201811:31 amRNSDirector/PDMR Shareholding
19th Nov 20187:00 amRNSAcquisition & Board Appointment
5th Nov 20188:35 amRNSIssue of Equity
17th Oct 20187:00 amRNSFinal Results
13th Sep 20187:00 amRNSNotice of Results
24th Aug 20187:00 amRNSIssue of Equity
23rd Aug 20187:00 amRNSIssue of Equity
19th Jul 20184:21 pmRNSHolding(s) in Company
19th Jul 20183:55 pmRNSHolding(s) in Company
16th Jul 20185:49 pmRNSResult of secondary placing
16th Jul 20181:53 pmRNSProposed secondary placing of Ordinary Shares
13th Jul 20187:00 amRNSTrading update & Notice of results
12th Jun 20184:39 pmRNSIssue of Equity
11th Jun 20182:37 pmRNSDirector/PDMR Shareholding
8th Jun 20187:00 amRNSShareholder Open Day
7th Jun 20188:15 amRNSIssue of Equity
1st Jun 20183:50 pmRNSDirector/PDMR Shareholdings
15th May 20188:14 amRNSHolding(s) in Company
11th May 20185:45 pmRNSDirector/PDMR Shareholding
10th May 20188:26 amRNSHolding(s) in Company
8th May 20189:51 amRNSIssue of Equity
2nd May 20184:55 pmRNSDirector/PDMR Dealing and Issue of Equity
23rd Apr 20187:00 amRNSEPA approval received
13th Apr 20182:55 pmRNSIssue of Equity
27th Mar 20188:19 amRNSIssue of Equity
26th Mar 20187:00 amRNSCommercial collaboration with Parker Laboratories
8th Mar 201810:58 amRNSIssue of Equity
20th Feb 20187:00 amRNSHalf-year Report
8th Feb 20182:19 pmRNSHolding(s) in Company
26th Jan 20187:00 amRNSIssue of Equity
24th Jan 20187:00 amRNSStudy shows comparable efficacy of Tristel Wipes
17th Jan 20187:00 amRNSInvestor results presentation
12th Dec 20172:57 pmRNSResult of AGM
12th Dec 20177:00 amRNSAGM Statement & notice of results
27th Nov 201710:35 amRNSIssue of Equity
23rd Nov 20173:24 pmRNSClarification of AGM timing
14th Nov 201710:34 amRNSIssue of Equity
2nd Nov 20177:00 amRNSDirectors dealing/grant of options
23rd Oct 20174:41 pmRNSIssue of Equity
19th Oct 20177:01 amRNSDirector Appointment
19th Oct 20177:00 amRNSFinal Results
3rd Oct 20177:00 amRNSTiming of EPA approval
19th Sep 20177:00 amRNSInvestor results presentation
18th Sep 20171:44 pmRNSIssue of Equity
22nd Aug 201712:08 pmRNSIssue of Equity
18th Aug 20171:31 pmRNSDirector/PDMR Dealing - replacement
17th Aug 20177:00 amRNSDirector/PDMR Dealing
7th Aug 20172:29 pmRNSIssue of Equity
24th Jul 20179:46 amRNSIssue of Equity
19th Jul 20177:00 amRNSTrading update & Notice of results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.